NMN/NR (Nicotinamide Mononucleotide/Riboside) and Testosterone Interaction

What Is the Interaction Between NMN/NR and Testosterone?

The combination does not carry a classical pharmacokinetic interaction. NMN and NR are not metabolized by CYP3A4, CYP2D6, or other major cytochrome P450 enzymes, and neither compound is a known P-glycoprotein substrate or inhibitor. Testosterone itself is primarily a CYP3A4 substrate. Because the two agents travel largely separate metabolic roads, plasma concentrations of testosterone are not expected to change when NMN or NR is added.

The concern is pharmacodynamic. Both agents touch overlapping biological systems, specifically erythropoiesis and lipid regulation, and combining them may amplify effects that each produces alone.

Why Pharmacodynamics Still Matter

A pharmacodynamic interaction does not require one drug to alter the blood level of another. It only requires that the two compounds push the same physiologic dial in the same direction. Testosterone drives erythropoiesis through EPO stimulation and direct effects on erythroid progenitor cells. NMN and NR replenish NAD+, and NAD+ is a required cofactor for SIRT1, which has been shown to regulate hypoxia-inducible factor-1-alpha (HIF-1alpha) activity, a key driver of erythropoietin transcription. That mechanistic thread is not yet proven in human TRT populations, but it is biologically plausible and worth clinical attention.

What the FDA Label Says About Testosterone and Blood Counts

The FDA-approved labeling for testosterone products lists polycythemia as an adverse reaction requiring monitoring. The label instructs prescribers to check hematocrit before initiating therapy, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, the label directs dose reduction, dose interruption, or therapeutic phlebotomy until hematocrit decreases to an acceptable level [1]. That threshold matters when layering on any supplement that might independently shift red cell mass.

How NMN and NR Work: The NAD+ Pathway

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors to NAD+. Both are converted intracellularly to nicotinamide adenine dinucleotide, the universal electron carrier involved in more than 500 enzymatic reactions.

NMN Metabolism

After oral ingestion, NMN is absorbed in the small intestine via a dedicated transporter (Slc12a8 in mice, with human homologs under active study) and converted to NAD+ primarily in the liver [2]. A 2023 human pharmacokinetic study found that a single 500 mg oral dose of NMN raised whole-blood NAD+ by roughly 38% within 2 to 3 hours in healthy adults [3].

NR Metabolism

NR follows a slightly different route. It is phosphorylated to NMN by NR kinases (NRK1 and NRK2) and then converted to NAD+. A 2016 randomized, double-blind, placebo-controlled crossover trial (N=12) by Trammell et al. Confirmed that oral NR at 300 mg and 1,000 mg doses raised whole-blood NAD+ in a dose-dependent manner without serious adverse events [4].

Why Sirtuins Connect NAD+ to Hematopoiesis

NAD+-dependent deacylases called sirtuins, particularly SIRT1 and SIRT3, regulate multiple pathways that can affect red blood cell production. SIRT1 deacetylates HIF-1alpha, altering its transcriptional activity and thereby influencing EPO gene expression in the kidney. Preclinical data from Zhang et al. (2016) showed that SIRT1 activation suppresses HIF-1alpha activity in normoxic conditions [5]. Whether this translates to a clinically meaningful increase in EPO in NAD-replete humans is unknown, but the pathway is intact.

Testosterone's Independent Effect on Hematocrit

Testosterone raises hematocrit through at least three mechanisms: it stimulates renal EPO synthesis, suppresses hepcidin (which increases iron availability for erythropoiesis), and may have direct effects on erythroid progenitors in bone marrow.

Incidence by Formulation

The route of administration matters. Injectable testosterone enanthate and cypionate produce supraphysiologic peaks that correlate with larger hematocrit elevations. A 2017 retrospective analysis found polycythemia (hematocrit above 50%) in up to 25% of men on injectable TRT vs. Approximately 4 to 5% on transdermal formulations [6]. Pellet implants carry intermediate risk.

Clinical Thresholds and Consequences

Hematocrit above 52 to 54% increases whole blood viscosity in a nonlinear fashion. Above 54%, the FDA label and Endocrine Society 2018 Clinical Practice Guideline on testosterone both recommend therapeutic intervention [1][7]. The Endocrine Society guideline states: "We suggest that clinicians withhold testosterone therapy during treatment of erythrocytosis until hematocrit is below 54%." [7]

Lipid Metabolism: The Second Overlap

Both testosterone and NAD+ biology touch lipid metabolism, but in ways that are not straightforwardly additive.

How Testosterone Affects Lipids

Exogenous testosterone lowers HDL cholesterol, often by 10 to 15%, through androgen-receptor-mediated upregulation of hepatic lipase. The effect is more pronounced with oral formulations and supraphysiologic dosing. A 2010 meta-analysis in JAMA (Fernández-Balsells et al., N=51 trials) found a mean HDL reduction of approximately 0.49 mmol/L with testosterone therapy [8]. LDL and triglyceride effects are variable and formulation-dependent.

How NAD+ Biology Affects Lipids

NAD+ is a required cofactor for SIRT1 and SIRT3, both of which deacetylate and activate LKB1-AMPK signaling. AMPK activation generally promotes fat oxidation and can lower circulating triglycerides. A 12-week randomized controlled trial of NR at 1,000 mg/day in obese men (N=40) by Dollerup et al. (2018) found no significant change in plasma lipids vs. Placebo, though the study was likely underpowered for lipid endpoints [9]. The clinical lipid interaction between NMN/NR and testosterone is therefore currently theoretical rather than demonstrated.

What This Means in Practice

Men on TRT who add NMN or NR should have a fasting lipid panel checked at baseline and at 6 months. This is standard care for TRT anyway, but the NAD-lipid connection provides an additional rationale. If triglycerides drop with NMN/NR supplementation, that would be a net cardiovascular benefit on top of TRT rather than a harm.

Polycythemia Risk: A Closer Look at the Additive Scenario

This is the most actionable concern for clinicians prescribing TRT to patients who also take NMN or NR.

Mechanistic Pathway Summary

1. Testosterone raises EPO via androgen-receptor signaling in the kidney.
2. Higher EPO drives erythroid progenitor proliferation and red cell mass.
3. NAD+ (restored by NMN/NR) activates SIRT1.
4. SIRT1 may modulate HIF-1alpha activity, which controls EPO transcription.
5. If NAD+ repletion increases HIF-1alpha-driven EPO synthesis, the two effects add.

Steps 1 and 2 are well-established in human data. Steps 3 through 5 are supported by preclinical mechanistic data but not yet confirmed by controlled human trials in TRT populations.

Current Evidence Gap

No randomized controlled trial has directly studied hematocrit change in men taking both testosterone and NMN/NR simultaneously. This is an evidence gap that HealthRX's medical team has identified as a priority for prospective cohort tracking.

HealthRX Polycythemia Risk Stratification for TRT + NMN/NR:

| Risk Tier | Profile | Monitoring Interval | |---|---|---| | Low | Transdermal TRT, hematocrit <46%, no sleep apnea | Every 6 months | | Moderate | Injectable TRT any dose, or hematocrit 46 to 50% | Every 3 months | | High | Injectable TRT + hematocrit 50 to 54%, or prior phlebotomy | Every 6 to 8 weeks | | Defer NMN/NR | Hematocrit above 54% at any point | Until hematocrit <50% after intervention |

This framework is based on FDA labeling thresholds [1], Endocrine Society 2018 guidelines [7], and clinical judgment from the HealthRX medical team. It has not been validated in a prospective trial.

Does NMN or NR Affect Testosterone Levels Directly?

One 2022 animal study (mice, N=40) showed that NMN supplementation at 300 mg/kg/day for 8 weeks raised serum testosterone in aged male mice vs. Controls, attributed to improved mitochondrial function in Leydig cells [10]. That dose does not translate linearly to humans (body surface area scaling would approximate 24 mg/kg/day in humans, roughly 1,600 to 1,700 mg/day for a 70 kg adult).

No peer-reviewed human trial has demonstrated that oral NMN or NR raises endogenous serum testosterone at commercially available doses (250 to 1,000 mg/day). Men on exogenous TRT suppress LH and FSH regardless, so endogenous Leydig cell output is already minimal. The mouse finding is mechanistically interesting but clinically irrelevant for men on TRT.

Drug Interaction Databases: What They Say

As of January 2025, major drug interaction databases including Lexicomp, Micromedex, and Drugs.com do not list a classified interaction between NMN/NR and testosterone. This is consistent with the absence of pharmacokinetic interaction data. The absence of a database flag does not mean the combination is risk-free; it means the pharmacodynamic overlap described above has not yet been formally adjudicated in those systems.

The FDA's adverse event reporting system (FAERS) contains no published signal as of the last publicly available quarterly report linking NMN/NR supplementation to testosterone-related hematologic events. That absence reflects the young age of NMN/NR as widely used supplements more than it reflects confirmed safety.

Practical Monitoring Protocol for Clinicians

Men starting NMN or NR while already on TRT should follow this sequence:

Baseline Labs Before Adding NMN/NR

• Complete blood count with differential
• Hematocrit (if not already checked within 6 weeks)
• Fasting lipid panel
• Basic metabolic panel
• PSA (if indicated by TRT protocol)

Follow-Up at 8 to 12 Weeks

Recheck hematocrit and CBC. If hematocrit has risen more than 3 percentage points from baseline, reduce NMN/NR dose by 50% and recheck in 6 weeks. If hematocrit crosses 54%, follow FDA label guidance and pause NMN/NR pending clinical decision.

Dose Considerations for NMN/NR on TRT

There is no human evidence that lower NMN/NR doses carry less erythrocytosis risk specifically. But prudence supports starting at the lower end of studied doses (250 mg/day NMN or 300 mg/day NR) in men on injectable testosterone with hematocrit already above 46%.

Patient Counseling Points

Men who ask about combining NMN/NR with their testosterone therapy should be told:

• The combination is not contraindicated based on available evidence.
• The main thing to watch is blood thickness, measured by hematocrit.
• Regular bloodwork is not optional. It is the safety mechanism.
• Energy and libido benefits from NMN/NR seen in some studies are real but modest in magnitude. They should not be used as a reason to skip monitoring.
• If dizziness, unusual headaches, facial flushing, or shortness of breath develop, they should contact their prescriber and request a same-week CBC.

The American Urological Association's 2023 Clinical Guideline on Male Hypogonadism states that "hematocrit should be measured at baseline, at 3 to 6 months, and annually thereafter; if hematocrit exceeds 54%, therapy should be withheld." [11] That guidance applies whether or not the patient is using NAD precursors.

Summary of the Evidence Quality

The evidence base for this specific interaction is thin by design: NMN and NR have only been studied in humans in significant numbers since roughly 2016, and TRT co-use was not a variable tracked in early trials. Here is where confidence is high vs. Where it remains speculative:

High confidence:

• No CYP-mediated pharmacokinetic interaction exists.
• Testosterone raises hematocrit in a dose- and formulation-dependent manner (strong human trial data).
• NAD+ regulates SIRT1 and HIF-1alpha in preclinical models.

Moderate confidence:

• Oral NMN and NR raise whole-blood NAD+ in humans at doses of 250 to 1,000 mg/day.

Low confidence / speculative:

• NMN/NR supplementation meaningfully raises hematocrit in humans.
• The hematocrit effects of testosterone and NMN/NR are additive in clinical practice.
• NMN/NR alters lipid parameters in TRT patients.

The clinically sound approach is to monitor as if the additive risk exists, because the monitoring is low-cost and the potential harm of unchecked erythrocytosis (increased stroke and VTE risk) is not trivial.